Full-Time
Radiologic Technologist
3D Modeling Tech
Alphatec Spine
1,001-5,000 employees
Develops and markets spinal surgery solutions
Compensation Overview
$56.5k - $70k/yr
No H1B Sponsorship
Memphis, TN, USA
In Person
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Alphatec Spine
See people who can refer or advise you
- Excellent knowledge of medical imaging and anatomy.
- Good skills with basic computer tools.
- A high school diploma is required.
- Graduation from an accredited radiologic technologist program is required.
- At least one year of experience in a hospital facility is required.
- Candidates must be eligible for and maintain credentials at all required hospitals, including meeting applicable physical or vaccination requirements where applicable.
- Candidates must be authorized to work in the United States without current or future employer sponsorship.
- Perform 3D spinal reconstruction and full-body alignment measurements on EOS radiographic images.
- Perform quality controls and additional verifications on each reconstructed or measured image.
- Participate actively in database creation for research and research and development activities.
- Follow and maintain the daily volumes expected and shared by the EOS3DServices Lead and AOS Production Manager.
- Document and share feedback on activities, tools, and processes with the EOS3DServices Lead and AOS Production Manager.
- Experience in 3D modeling and segmentation techniques is a plus.
- Adaptability to a fast-paced environment.
Alphatec Spine develops and sells implants, instruments, and integrated technologies for spine surgery, including devices used in fusion procedures and related navigation or imaging systems gained through acquisitions like SafeOp Surgical. During surgery, surgeons use these implants and instruments, often with imaging or navigation tools to plan and guide the procedure, while the implants support fusion and healing. It differentiates itself with a broad product portfolio and enhanced technology through strategic acquisitions, giving it capabilities in navigation and advanced spine solutions beyond a narrow line of implants. Its goal is to improve spinal surgery outcomes and expand access to effective spine-care solutions.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Carlsbad, California
Founded
1990
Get referred to Alphatec Spine
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 4, 2026 Q2 revenue reached $214 million, up 15%, with EBITDA margin 17%.
- Alphatec raised 2026 adjusted EBITDA guidance to $140 million and kept $882 million revenue.
- The May 2026 bank facility cut interest expense over $6 million and extends maturity to 2031.
What critics are saying
- May 2026 EOS installation failures cut guidance and triggered 32% share collapse.
- Multiple law firms opened securities investigations after Alphatec admitted unfulfilled committed units.
- Persistent losses and heavy leverage make a second guidance miss existential if hospital adoption slows.
What makes Alphatec Spine unique
- Alphatec integrates EOS imaging, SafeOp neuromonitoring, and Valence into one spine workflow.
- EOS Insight adoption lifted implant revenue 32% within six months, per August 2026 management.
- The company sells proceduralization, not implants alone, tying software, imaging, and surgery together.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Sick Leave
Paid Holidays
Disability Insurance
Stock Options
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↓ -3%2 year growth
↓ -3%Alphatec Holdings reported strong Q2 2026 results with total revenue of $214 million, up 15% year-over-year, and surgical revenue of $196 million, up 17%. The medical device company saw adjusted EBITDA rise 53% to $36 million, with margins expanding 420 basis points to 17%. The company added 24% more net new surgeons and posted 20% case volume growth. Gross margin improved 260 basis points to 72.5%, driven by better inventory efficiency and favourable product mix. Alphatec generated positive free cash flow of approximately $1 million in Q2 and raised full-year adjusted EBITDA guidance to $140 million from $134 million previously. However, revenue per case declined 2.7% due to case mix shifts and international growth. The company now expects full-year revenue per case to decline in the low single digits, citing slower biologics attachment improvement.
Alphatec, a spine surgery technology company, reported revenue of $764.2 million in FY 2025, up 25% year-over-year, but posted a net loss of $143.4 million. The company's debt-to-equity ratio stands at approximately 17.2x, whilst its current ratio is 2.1x. Stock-based compensation represented roughly 163% of operating cash flow. Inspire Medical Systems specialises in neurostimulation therapy for obstructive sleep apnea patients who cannot use standard breathing machines. The company targets sleep specialists and ENT surgeons globally. Alphatec differentiates itself through an integrated ecosystem using subsidiaries like EOS imaging and SafeOp Surgical, serving primarily the US hospital market whilst expanding into Europe and Japan. Both companies operate in medical technology but represent different maturity levels and financial profiles for investors seeking healthcare device exposure.
Alphatec Holdings, a medical technology company specialising in spinal surgery solutions, reported strong first-quarter 2026 results with surgical revenue up 17% and total revenue growing 14% to $192 million. The company achieved non-GAAP adjusted EBITDA of $21 million whilst securing a new bank facility that reduces annual interest expenses by over $6 million. Growth was driven by a 21% increase in surgical case volume and 23% rise in net new surgeon users. The company reported an ending cash balance of $140 million and trailing twelve-month free cash flow of $7 million. For full-year 2026, Alphatec expects total revenue of approximately $882 million, representing 15% growth, with adjusted EBITDA projected at $134 million and at least $20 million in free cash flow generation.
Kirby McInerney LLP is investigating potential securities law violations by Alphatec Holdings and its senior management following a sharp share price decline. On 5 May 2026, Alphatec reported first quarter revenue of $192 million and disclosed that EOS revenue, from its proprietary imaging platform, was $14 million—below internal expectations. The company reduced its full-year 2026 EOS revenue guidance to approximately $77 million from $85 million, citing execution issues with equipment installations. Management stated that "installation timing was a challenge" and the company failed to fulfill committed units. Following the announcement, Alphatec shares fell 32%, from $10.23 to $6.99 per share. No lawsuit has been filed yet, and the investigation is ongoing to determine whether claims may be brought under federal securities laws.
Alphatec Holdings shares fell 25% to $6.99 following its first-quarter results, which showed revenue of $192 million, falling 2.3% short of analyst estimates. Statutory losses of $0.22 per share were 12% smaller than expected. Following the results, eleven analysts revised their forecasts, maintaining revenue expectations of $881.8 million for 2026, representing 12% growth. They improved loss predictions to $0.52 per share, down from $0.55 previously. However, the average price target fell 26% to $18.00, with individual targets ranging from $11.00 to $25.00. Analysts expect Alphatec Holdings' revenue growth to slow to 16% annually through 2026, down from 28% over the past five years, though this remains above the industry average of 8%.